Clinical trial
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
NCT00059462 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00059462 |
|---|---|
| Title | Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection |
| Official title | Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Interleukin-2 SA, HAART |
| Enrollment | 56 |
| Start date | Dec 1, 2002 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Jun 2, 2003 |
| Last update posted | Dec 23, 2014 |
| Countries | France, United Kingdom, United States |
At a glance
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: